Publication|Articles|May 28, 2026
Supplements and Featured Publications
- Myelofibrosis Treatment: Health Economic Considerations
Myelofibrosis Treatment: Health Economic Considerations
This Clinical Brief is intended for payers, formulary committee members, drug selection panels, and other similar multidisciplinary individuals or entities. It contains health care economic information to aid in the selection of drugs for coverage or reimbursement. It is not intended for health care providers making individual prescribing decisions or for consumers.
Advertisement
This Clinical Brief was sponsored by Incyte.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs
2
EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”
3
Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV
4
5 Ongoing Clinical Trials in Myeloproliferative Neoplasms
5
